The Technical AnalystExchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
NRx Pharmaceuticals, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.56% $0.190
/ 17 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 15.81 mill |
| EPS: | -6.25 |
| P/E: | -0.0300 |
| Earnings Date: | Mar 30, 2023 |
| SharesOutstanding: | 83.20 mill |
| Avg Daily Volume: | 0 mill |
| RATING 2024-04-17 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Buy | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0300 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.0300 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.603 (-417.20%) $-0.793 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.168 - 0.212 ( +/- 11.58%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-28 | Rehnquist Janet | Buy | 0 | |
| 2023-09-13 | Narido Richard Clavano | Buy | 0 | |
| 2023-08-30 | Gorovitz Aaron | Buy | 35 000 | Common Stock, par value $0.001 per share |
| 2023-08-30 | Hurvitz Chaim | Buy | 70 000 | Common Stock, par value $0.001 per share |
| 2023-08-23 | Javitt Jonathan C | Buy | 100 000 | Common Stock |
| INSIDER POWER |
|---|
| 58.90 |
| Last 31 transactions |
| Buy: 2 175 064 | Sell: 638 108 |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.190 (-2.56% ) |
| Volume | 0.0061 mill |
| Avg. Vol. | 0 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NRXPW
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NRXPW
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.